Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

for
Cervical Cancer,
Location: Hackensack NJ, Montreal, Hamilton, Nashville TN,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT04895709

Phase 1, Phase 2, Recruiting

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

for
Ovarian Cancer
Location: New York NY, Newport News VA, Baltimore MD, York PA,
Sponsor: NX Development Corp

Sex: Female

Age: 18+

Code: NCT05804370

Phase 3, Recruiting

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

for
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: Female

Age: 18+

Code: NCT06543537

Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

for
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Location: Pittsburgh PA
Sponsor: Alexander B Olawaiye, MD

Sex: Female

Age: 18+

Code: NCT05071937

Phase 2, Recruiting

Cancer Prevention in Women With a BRCA Mutation

for
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Cancer,
Location: Toronto
Sponsor: Women's College Hospital

Sex: Female

Age: 35 - 70

Code: NCT02225015

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

for
Non Small Cell Lung Cancer, Esophageal Cancer,
Location: Boston MA, New Haven CT, New York NY,
Sponsor: SystImmune Inc.

Sex: All

Age: 18+

Code: NCT05983432

Phase 1, Recruiting

Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer

for
Ovarian Cancer
Location: Charlottesville VA
Sponsor: University of Virginia

Sex: Female

Age: 18 - 70+

Code: NCT01187602

Recruiting

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

for
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18 - 70+

Code: NCT01174121

Phase 2, Recruiting

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

for
Ovarian Cancer, Fallopian Tube Cancer,
Location: Toronto
Sponsor: University Health Network, Toronto

Sex: Female

Age: 18+

Code: NCT05065021

Phase 2, Recruiting

NYSCF Scientific Discovery Biobank

for
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease,
Location: New York NY
Sponsor: New York Stem Cell Foundation Research Institute

Sex: All

Age: 0+

Code: NCT06203106

Recruiting

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

for
Triple Negative Breast Cancer, Breast Cancer,
Location: Boston MA, New York NY, Fairfax VA, Jacksonville FL,
Sponsor: Day One Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT05377996

Phase 1, Phase 2, Recruiting

Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer

for
Ovarian Cancer
Location: Albuquerque NM
Sponsor: New Mexico Cancer Research Alliance

Sex: Female

Age: 18+

Code: NCT03943316

Recruiting

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

for
Educational Materials for Genetic Testing, Breast Cancer,
Location: Jamaica NY, Richmond Hill NY, Brooklyn NY, New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT04751435

Recruiting

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

for
Platinum-resistant Ovarian Cancer, Testicular Cancer,
Location: Boston MA, Providence RI, New York NY, Durham NC,
Sponsor: Context Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT06515613

Phase 1, Recruiting

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

for
Breast Cancer, Ovarian Cancer
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: Female

Age: 21+

Code: NCT06430541

Phase 1, Recruiting

Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

for
Ovarian Cancer
Location: Quebec, Montreal, Toronto, Edmonton, Vancouver,
Sponsor: University College, London

Sex: Female

Age: 18+

Code: NCT03278717

Phase 3, Recruiting

Prehabilitation for Ovarian Cancer Patients

for
Prehabilitation, Exercise, Frailty, Ovarian Cancer,
Location: Halifax
Sponsor: Nova Scotia Health Authority

Sex: Female

Age: 18+

Code: NCT05364879

Recruiting

Spanish Decision Tool for Ovarian Cancer Maintenance Therapy

for
Ovarian Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06036810

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

for
Low Grade Serous Ovarian Cancer
Location: New Haven CT, New York NY, Montreal, Philadelphia PA,
Sponsor: Verastem, Inc.

Sex: Female

Age: 18+

Code: NCT06072781

Phase 3, Recruiting

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

for
Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer,
Location: Charleston SC, Portland OR, Duarte CA
Sponsor: Adela, Inc

Sex: All

Age: 40+

Code: NCT05366881

Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial